Dajti, E, Villanueva, C, Berzigotti, A, Brujats, A, Albillos, A, Genescà, J, García-Pagán, JC, Colecchia, A, Bosch, J. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial. JOURNAL OF HEPATOLOGY. 2025; 82(3)DOI:10.1016/j.jhep.2024.09.014. PMID:39303875. IF:33.000(Q1/1D).

Añez, G, Torrente-Segarra, V, Bonet, M, Vilella, MC, Orpinell, L, Fernández, AP, Busquets-Pérez, N, Pascual-Pastor, M, Corominas, H, Diaz-Torne, C, Moya, P, De Agustin, JJ. Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool?. Journal Of Ultrasound. 2025; 28(1)DOI:10.1007/s40477-024-00963-z. PMID:39424691. IF:(Q/D).

Piedra, A, Guinart-Cuadra, A, Recio, SM, Mulet, M, Atenza, CZ, Alejandre, J, Beltran, JS, Joaquín, AB, Sullivan, IG, López, JS, Casado, MDI, Aperribay, EA, Paz-Ares, L, Tain, PD, Vega, ALM, Callejo, A, Martos, JLL, Dominguez, M, Vidal, S, Majem, M. Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, O'Byrne, KJ, Lo Russo, G, Mueller, C, Triebel, F. TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).